Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Treatment simplification strategies news

Show

From To
FDA approves first two-drug complete regimen for HIV-infected patients who have never received antiretroviral treatment

The U.S. Food and Drug Administration today approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the individual components of Dovato. This is the first FDA-approved two-drug, fixed-dose, complete regimen for HIV-infected adults who have never received treatment for HIV.

Published
09 April 2019
From
Food & Drug Administration
ViiV Healthcare announces Juluca (dolutegravir/rilpivirine) maintains HIV viral suppression at 148-weeks

SWORD studies demonstrate long-term durable efficacy and tolerability of Juluca, the first complete 2-drug regimen, for the treatment of virologically suppressed adults with HIV

Published
05 April 2019
From
ViiV press release
Two-antiretroviral maintenance failure - raltegravir regimens seem most vulnerable

Two-antiretroviral maintenance regimens failed virologically in only 3.5% of 3484 people in a 2010-2017 French analysis. Raltegravir/etravirine (RAL/ETR) and raltegravir plus darunavir/ritonavir (DRV/r/RAL) appeared to be the duos most vulnerable to virologic failure. Other failure risk factors included highest viral load above 100,000 copies and a previous virologic failure.

Published
29 March 2019
From
NATAP
Laura Waters, MD, FRCP: Can Two Drugs Tango?

In a symposium presentation at the Annual Conference on Retroviruses and Opportunistic Infections (CROI 2019), Laura Waters, MD, FRCP, discussed the developments of 2-drug regimens for HIV treatments, as well as the questions that remain unanswered. Contagion® sat down with Dr. Waters for an exclusive interview about her presentation and to discuss new data from several studies presented at the meeting.

Published
12 March 2019
From
Contagion Live
Early ART in HIV Possible Key to Dolutegravir Monotherapy Success

Several randomized controlled trials have shown dolutegravir monotherapy to be inferior to cART. These dolutegravir monotherapy trials, however, have been conducted in patients initiating cART during chronic rather than primary HIV infection. Since patients who start cART during the early phase of HIV infection show a reduced HIV reservoir and low viral diversity, the researchers evaluated whether these properties would allow for sustained virologic suppression after a switch to dolutegravir monotherapy.

Published
15 February 2019
From
Infectious Disease Advisor
Six advantages of dolutegravir

Dolutegravir is a critically important antiretroviral medicine that is set to become the backbone of South Africa and many other countries’ HIV programmes. While the drug has recently made headlines because of a potential safety risk, most of what we know about the medicine indicates that it represents an important improvement over existing medicines.

Published
28 January 2019
From
Spotlight SA
Dolutegravir Monotherapy for HIV No Longer Recommended

Dolutegravir monotherapy should no longer be used as HIV maintenance therapy, according to Bart J.A. Rijnders, MD, PhD, and Casper Rokx, MD, PhD, both from Erasmus Medical Center, Rotterdam, the Netherlands.

Published
09 January 2019
From
Contagion Live
Top 10 HIV Clinical Developments of 2018

It's the beginning of the end. Not in some apocalyptic way, but rather in how we think about the prevention and management of HIV.

Published
20 December 2018
From
The Body Pro
Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

GlaxoSmithKline subsidiary ViiV Healthcare believes its portfolio of HIV medications will be competitive as treatment for the virus enters an era of two-drug regimens. So far, however, the company's first doublet has performed modestly on the market compared to a key rival's three-drug regimen.

Published
12 December 2018
From
BioPharma Dive
Dual HIV Regimen Equaled Triple Even After Treatment Failure

A "dual" combination of raltegravir (Isentress) plus boosted protease inhibitor was comparable to triple combination regimens with raltegravir for HIV in treatment-experienced patients, including those with previous treatment failure, in a retrospective study with real-world cohort.

Published
26 November 2018
From
MD Magazine
← First123...4Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.